Developed, clinically validated, and studied in over 5,000 patients1-15
>5,000
Patients1-15
The Oncotype DX GPS test was specifically designed to guide treatment decisions in patients with clinically low- or intermediate-risk prostate cancer. Over 5,000 patients have been included in development studies, clinical validation studies, and clinical utility studies.1-15
Clinical validation studies
The clinical validation studies for the Oncotype DX Genomic Prostate Score (GPS) test were conducted in a prospective fashion (using retrospective cohorts) from large, contemporary databases:
- Kaiser Permanente, Northern California (KPNC) (N=259).1
- University of California, San Francisco (UCSF) (N=395).2
- Center for Prostate Disease Research (CPDR) (N=402).3
A meta-analysis combining the UCSF and CPDR cohorts (N=732)9 validated the association between the Oncotype DX GPS test and refined estimation of the likelihood of adverse pathology.
20-Year outcomes16
Study suggests that the Oncotype DX GPS assay may be prognostic for both distant metastasis and prostate cancer-specific mortality through 20 years after diagnosis, and that the GPS assay together with clinical factors may improve risk assessment over clinical factors alone.
16